Literature DB >> 34492239

Rebound of cyst number following discontinuation of guanabenz treatment for latent toxoplasmosis.

Jennifer Martynowicz1, William J Sullivan2.   

Abstract

Toxoplasma gondii is a protozoan parasite that causes opportunistic infection in immunocompromised individuals. The parasite forms latent tissue cysts that are refractory to current treatments and give rise to life-threatening reactivated infection following immune suppression. Previously, we showed that guanabenz sharply reduces brain cyst count in BALB/c mice harboring latent toxoplasmosis; however, whether cyst count would change once drug treatment stopped was not addressed. In the present study, we observed a rebound in brain cysts following the discontinuation of guanabenz or a guanabenz-pyrimethamine combination therapy. The re-expansion of brain cysts was not accompanied by symptoms of acute toxoplasmosis. We also tested whether the rebound in cyst counts could be ameliorated by administering pyrimethamine during or after guanabenz treatment.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-infective drugs; Guanabenz; Host-pathogen interactions; Parasites; Toxoplasma

Mesh:

Substances:

Year:  2021        PMID: 34492239      PMCID: PMC8484070          DOI: 10.1016/j.molbiopara.2021.111411

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.845


  13 in total

1.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

2.  Treatment of toxoplasmic encephalitis with intravenous clindamycin.

Authors:  B R Dannemann; D M Israelski; J S Remington
Journal:  Arch Intern Med       Date:  1988-11

3.  Latent toxoplasmosis is associated with neurocognitive impairment in young adults with and without chronic HIV infection.

Authors:  L Ene; T D Marcotte; A Umlauf; C Grancea; A Temereanca; A Bharti; C L Achim; S Letendre; S M Ruta
Journal:  J Neuroimmunol       Date:  2016-08-04       Impact factor: 3.478

4.  Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii.

Authors:  Christian Konrad; Sherry F Queener; Ronald C Wek; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

5.  Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

Authors:  C Katlama; S De Wit; E O'Doherty; M Van Glabeke; N Clumeck
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

6.  Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis.

Authors:  Imaan Benmerzouga; Lisa A Checkley; Michael T Ferdig; Gustavo Arrizabalaga; Ronald C Wek; William J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

7.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

Review 8.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

9.  Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation.

Authors:  Jennifer Martynowicz; Leonardo Augusto; Ronald C Wek; Stephen L Boehm; William J Sullivan
Journal:  MBio       Date:  2019-04-30       Impact factor: 7.867

10.  Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries.

Authors:  Jaroslav Flegr; Joseph Prandota; Michaela Sovičková; Zafar H Israili
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.